Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026
Region:Global
Product Code:GDHC168PIDR
June 2018
187
About the Report
Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026
Summary
Dry Eye Syndrome (DES) is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. With a rapidly accelerating worldwide prevalence and the limited treatment options available, there is a growing pressure for new therapies and curative treatment for DES patients. Significant efforts are being made to develop a new treatment for DES, as current pharmacologic management is known to only provide temporary symptomatic relief.
GlobalData estimates the 2016 sales for DES at approximately USD 2.2B across the 8MM covered in this report.
The DES pipeline activity comprises 10 active Phase III (or Phase II/III) pipeline agents with novel mechanisms of action as well as cyclosporines with improved clinical profiles. Additionally, six of these late-stage pipeline drugs are expected to be first-in-class therapies. The most notable pipeline drugs include RegeneRx's thymosin beta-4 product RGN-259, Aldeyra's reproxalap which acts as an aldehyde trap, and Sylentis' TRPV1 inhibitor tivanisiran. Other late-phase novel drugs include Mitotech's mitochondrial antioxidant product visomitin, Kala Pharmaceuticals' corticosteroid KPI-121, and Novartis' and Dompe's recombinant human lubricin protein ECF-843. GlobalData expects these new drugs will expand the DES treatment options and contribute to overall market growth. Nevertheless, considerable opportunities remain within this severely underserved DES market.
Key Questions Answered
- What are the key unmet needs clinically and in research? What do KOLs identify as the key unmet needs? Will the products in the DES pipeline fill these unmet needs?
- When are the pipeline products expected to launch? What are the key features of the products in the pipeline?
- What are the threats for drugs currently on the market? How will the new pipeline products be incorporated into the current treatment algorithm?
- What are the key hurdles for manufacturers entering the DES market?
Scope
- Overview of DES: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized DES market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild DES, moderate DES, and severe DES), forecast from 2016 to 2026.
- Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DES therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DES therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.
- Analysis of the current and future market competition in the global DES therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to-
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global DES therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DES therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Scope of the Report
Products
Companies
Allergan
Santen
Shire
RegeneRx
Aldeyra
Sylentis
Sun Pharmaceutical
Novartis
Dompe
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 DES: Executive Summary 6
2.1 DES Therapeutics Market Will Grow to USD 5.6B by 2026 7
2.2 DES Is a High Risk Indication for Drug Development 9
2.3 While New Therapeutics Enter the DES Market, Unmet Needs Persist 10
2.4 Significant Opportunities Remain Within the DES Market to Fulfill Unmet Needs 11
2.5 Newly Approved Therapeutics Will Improve Treatment Options for DES Patients 11
2.6 What Do Physicians Think? 13
3 Introduction 15
3.1 Catalyst 15
3.2 Related Reports 15
3.3 Upcoming Related Reports 16
4 Disease Overview 17
4.1 Etiology and Pathophysiology 17
4.2 Disease Classification 22
5 Epidemiology 24
5.1 Disease Background 24
5.2 Risk Factors and Comorbidities 24
5.3 Global and Historical Trends 25
5.4 Forecast Methodology 26
5.5 Epidemiological Forecast for DES (2016-2026) 34
5.6 Discussion 39
6 Disease Management 42
6.1 Diagnosis and Treatment Overview 42
6.2 US 57
6.3 5EU 61
6.4 Japan 66
6.5 China 72
7 Competitive Assessment 76
7.1 Overview 76
7.2 Marketed Therapies and Artificial Tears for DES 78
7.3 Other Therapies 78
8 Unmet Needs and Opportunity Assessment 81
8.1 Overview 81
8.2 New Therapies for DES 82
8.3 Better Diagnostic Tools 88
8.4 Appropriate Clinical Trial Design 92
8.5 Simplified Dosing 96
9 Pipeline Assessment 99
9.1 Overview 99
9.2 Promising Drugs in Clinical Development 102
9.3 Promising Drugs in Early-Stage Development 105
10 Current and Future Players 110
10.1 Overview 110
10.2 Trends in Corporate Strategy 112
10.3 Allergan 114
10.4 Santen 117
10.5 Shire 119
10.6 RegeneRx 121
10.7 Aldeyra 123
10.8 Sylentis 124
10.9 Sun Pharmaceutical 125
10.10 Novartis 127
10.11 Dompe 128
11 Market Outlook 130
11.1 Global Markets 130
11.2 US 133
11.3 5EU 138
11.4 Japan 142
11.5 China 146
12 Appendix 150
12.1 Bibliography 150
12.2 Abbreviations 163
12.3 Methodology 166
12.4 Primary Research-Key Opinion Leaders Interviewed for This Report 178
12.5 Primary Research-Prescriber Survey 182
12.6 About the Authors 182
12.7 About GlobalData 185
12.8 Contact Us 186
12.9 Disclaimer 186
Research Methodology
Why Buy From Us?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.